Medical Diagnostic Developer MELA Sciences to Present at SeeThruEquity Microcap Conf. Feb. 6 in NYC and to Exhibit at Maui

  Medical Diagnostic Developer MELA Sciences to Present at SeeThruEquity
  Microcap Conf. Feb. 6 in NYC and to Exhibit at Maui Dermatology Conf. Jan.

         Presentation Audio and Slides Available Live and Via Webcast

Business Wire

NEW YORK -- January 27, 2014

MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind^®, an FDA approved
optical diagnostic device that assists dermatologists in the diagnosis of
melanoma, today announced its CEO, Rose Crane, will present at the
SeeThruEquity Winter Microcap Investor Conference on February 6, 2014 at 9:30
am ET in New York. Ms. Crane; Robert Coradini, Chairman; Mary Phellan,
Controller; and Diana Garcia Redruello, head of the MelaFind Commercial Team
will be available for one-on-one meetings that day.

Ms. Crane will review the Company’s refocused go-to-market strategy for
MelaFind^®, including its sales and marketing efforts targeting leading
medical dermatologists in the U.S. and Europe.

Access to the webcast and presentation will be available live during the
conference at 9:30am EST on February 6, 2014 via the following links:

Live Audio Webcast: MELA Sciences' Webcast
Presentation Slides: MELA Sciences' Corporate Presentation

MELA Sciences will also be participating at the 10^th Annual Maui Derm
Conference at the Grand Wailea Hotel, January 26 – 30, 2014. The conference is
designed to increase physicians’ knowledge of developments in both medical and
cosmetic dermatology. MELA will exhibit four clinical posters at the event as
well as host a MelaFind^® workshop on Sunday, January 26. Dr. Monica Scheel,
who recently presented new real-world clinical data at MELA Sciences’ Clinical
Advisory meeting at the Winter Clinical Dermatology Conference – Hawaii^® last
week, will host the workshop.

Please follow us:

Twitter: @MELASciencesIR or @MelaFind
StockTwits: @MELASciencesIR

About MELA Sciences, Inc.

MELA Sciences is a medical device company developing dermatology diagnostics
utilizing state-of-the-art optical imaging. The flagship product is
MelaFind^®, an FDA, PMA and CE Mark approved, non-invasive diagnostic tool to
aid dermatologists in melanoma evaluation and diagnosis. MelaFind^® uses a
variety of visible to near-infrared light waves to evaluate skin lesions from
the surface to 2.5 mm beneath the skin. It provides images and data on the
relative disorganization of a lesion's cell structure that provides
substantial additional perspective to aid melanoma diagnosis. MELA is also
exploring new potential uses for its core imaging technology and algorithms.


MELA Sciences, Inc.
Diana Garcia Redruello, 914-591-3783
Catalyst Global
Toni Trigiani
David Collins
Press spacebar to pause and continue. Press esc to stop.